EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Safety and Efficacy of HL301 In Radiation Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Receiving Curative Concurrent Chemoradiotherapy: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2a Clinical Trial

Kyung Hwan Kim, Nahyun Kang, Si Yeol Song, Hak Jae Kim, Yeon-Sil Kim, Mi Jin Oh, Jaeho Cho

International Journal of Radiation Oncology*Biology*Physics · 2024

DOI: 10.1016/j.ijrobp.2024.03.033 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Kyung Hwan Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Republic …. Hauptthemen laut MEDLINE: Radiation Pneumonitis, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Korea Ministry of Health and Welfare, Korea Health Industry Development Institute, Ministry of Science, ICT and Future Planning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We aimed to investigate the safety and efficacy of HL301, a standardized combination product of 7 medicinal plants, in radiation pneumonitis in patients with unresectable non-small cell lung cancer undergoing curative concurrent chemoradiotherapy. METHODS AND MATERIALS: The target accrual was 87 and a total of 63 patients were enrolled due to poor accrual rate. We randomly assigned the 63 patients to receive a placebo (arm A), or 1200 mg HL301 (arm B), or 1800 mg HL301 (arm C). Patients received weekly paclitaxel and carboplatin concurrently with intensity-modulated radiation therapy at 60 to 66 Gy in conventional fractionation. Durvalumab was administered as a maintenance treatment according to standard clinical practice. HL301 was administered orally, daily for 12 weeks. The primary endpoint was incidence of grade ≥2 radiation pneumonitis at 24 weeks postchemoradiotherapy. RESULTS: The baseline characteristics of the patients were well balanced. The drug was tolerable with a compliance rate of 86.6%, 86.2%, and 88.8% in arms A, B, and C, respectively (P = .874). None of the patients experienced severe drug-related adverse events. No significant difference in the rate of adverse events were observed between the treatment arms. The incidence of grade ≥2 radiation pneumonitis at 24 weeks postchemoradiotherapy was 37.5% (95% CI, 18.5%-61.4%), 55.6% (95% CI, 33.7%-75.4%), and 52.4% (95% CI, 32.4%-71.7%) in arms A, B, and C, respectively (P = .535). CONCLUSIONS: This is the first exploratory clinical trial to test the safety and efficacy of HL301 in patients with non-small cell lung cancer. Safety and feasibility of HL301 were established but no signals of efficacy in reducing radiation pneumonitis was observed in this dose level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Radiation PneumonitisCarcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyCarboplatinPaclitaxelAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodRadiotherapy, Intensity-ModulatedAntibodies, MonoclonalAdult

Substanzen

CarboplatinPaclitaxeldurvalumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea; R&D Center, Hanlim Pharm. Co, Ltd, Seoul, Republic of Korea.
  • Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
  • R&D Center, Hanlim Pharm. Co, Ltd, Seoul, Republic of Korea.

Förderung

  • Korea Ministry of Health and Welfare
  • Korea Health Industry Development Institute
  • Ministry of Science, ICT and Future Planning
  • National Research Foundation of Korea

Zitieren

APA

Kim, K. H., Kang, N., Song, S. Y., Kim, H. J., Kim, Y. S., Oh, M. J., & Cho, J. (2024). Safety and Efficacy of HL301 In Radiation Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Receiving Curative Concurrent Chemoradiotherapy: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2a Clinical Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.03.033

Vancouver

Kim KH, Kang N, Song SY, Kim HJ, Kim YS, Oh MJ, et al. Safety and Efficacy of HL301 In Radiation Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Receiving Curative Concurrent Chemoradiotherapy: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2a Clinical Trial. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2024.03.033

BibTeX
@article{Kim2024,
  author = {Kim, Kyung Hwan and Kang, Nahyun and Song, Si Yeol and Kim, Hak Jae and Kim, Yeon-Sil and Oh, Mi Jin and Cho, Jaeho},
  title = {Safety and Efficacy of HL301 In Radiation Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Receiving Curative Concurrent Chemoradiotherapy: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2a Clinical Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  doi = {10.1016/j.ijrobp.2024.03.033}
}
Kostenlos starten →